Related Experiment Video
Updated: Apr 29, 2026
Development and Standardization of an Ex Vivo Micromethod for Intracellular Quantification of Vincristine in Primary ALL Cells by LC-MS/MS
Published on: January 23, 2026
Vincristine and irinotecan in children with relapsed hepatoblastoma: a single-institution experience
Yu-tong Zhang1, Li-hua Feng, Xiao-dan Zhong
11Department of Pediatric Hematology and Oncology, the First Hospital of Jilin University, Changchun, Jilin, China.
Purpose:
This study was to determine the efficacy of vincristine and irinotecan in children with relapsed hepatoblastoma (HB).
Methods:
A total of 10 patients with relapsed HB were enrolled. Three patients were excluded. Patients received irinotecan 50 mg/m(2)/day, day 1-5 and vincristine 1.5 mg/m(2)/day, day 1, repeated every 3 weeks. The maximum cycles were eight. Reevaluation of tumor was performed every two cycles. The primary outcome was the rate of complete resection. Secondary outcomes were event-free survival (EFS) and overall survival (OS).
Results:
Of the seven patients assessable for response, one patient with normal AFP level showed a progressive disease and withdrew. He finally died 6 months later. Four had PR, all of them underwent a second surgery and achieved complete resection. Two patients had SD, one patient relapsed 6 months after orthotopic liver transplantation and died, the other one undergoing surgery had micro margin positive, he relapsed again but alive. The rate of complete resection was 71.4% (including orthotopic liver transplantation). The 2-year EFS and OS for the whole group were 57.1% (95% CI, 12.7% to 34.2%) and 71.4% (95% CI, 16.39% to 37.4%), respectively.
Conclusions:
The combination of irinotecan and vincristine has a significant antitumor activity and acceptable toxicity in children with relapsed HB.
